OGEN SA decided to prolong their equity crowdfunding campaign which succeeded with quarter million euros gathered during the last 30 days. More than 420 investors have already bought OGEN SA shares. One of the most significant benefits that one gets when investing is a free DNA test with a superb breakdown and interpretation of one’s results.

Starting with 61 shares (for about 584 euros) investors get not only OGEN shares, but also a lifestyle DNA test, (which will soon be translated into English and other European languages).

OGEN already provides reports containing broad lifestyle interpretations and is now preparing diagnostic grade prevention tests.

With 244 shares (for about 2333euros) investors will get access to these upcoming tests as well.

OGEN aims to become Europe’s go to solution for Consumer DNA tests.

A report recently released by Deloitte estimates that more than 20 billion Euros could be saved with by immediate, and diagnostic grade prevention tests, in just Poland alone.

DNA testing is the earliest prevention method with regards to oncological and cardiological diseases which combined make up the cause of death of 70% of Europeans.

OGEN Chairman of the supervisory board says: “Soon, in developed countries, DNA tests will be performed routinely at birth, it will prevent an enormous amount of suffering and healthcare spending. We are ready to provide those tests with high capacity. The final step is raising awareness and making it a standard diagnostic tool.”

OGEN SA seems to be the only company which is not forcing customers to give away their data to pharmaceutical companies. Customers can choose to allow their data to be used in scientific research, but even that is not compulsory.

Buy shares and find more information at ogen.beesfund.com/en/ or contact mk@ogen.pl

Media Contact
Company Name: OGEN SA
Contact Person: Mateusz Kowalczyk
Email: Send Email
Phone: +48882909474
Country: Poland
Website: ogen.beesfund.com/en/